MIM
MAZE

MetLife Investment Management’s Maze Therapeutics MAZE Stock Holding History

MetLife Investment Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$434K Buy
14,542
+2,741
+23% +$121K ﹤0.01% 1826
2025
Q4 		$489K Hold
11,801
– – ﹤0.01% 1799
2025
Q3 		$306K Buy
+11,801
New +$199K ﹤0.01% 2073

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's MAZE Position: Q1 2026 in Review

MetLife Investment Management increased its Maze Therapeutics (MAZE) stake by 23% in Q1 2026, buying an estimated $121K and bringing the position to 14,542 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #1826.

MetLife Investment Management first reported a position in MAZE in Q3 2025 and has held it in 3 quarters since. The position peaked at $489K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • MetLife Investment Management held 14,542 shares of Maze Therapeutics worth $434K as of Q1 2026.
  • MetLife Investment Management bought 2,741 Maze Therapeutics shares in Q1 2026, an estimated $121K.
  • Maze Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1826 holding.
  • MetLife Investment Management first reported a position in Maze Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • MetLife Investment Management's Maze Therapeutics position peaked at $489K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.